

**GBSC Meeting Copenhagen – July 12th 2014** 

## **Diagnostic Assays for Alzheimer's Disease Biomarkers** *Tobias Bittner, Roche Diagnostics*






The following presentation will discuss products that are not FDA cleared/approved yet.

### Agenda

- Roche Diagnostics
- Roche AD Biomarker Development Program
- Analytical Performance Abeta42
- Preliminary Analytical Performance tTau
- Preliminary Analytical Performance pTau181



### **Roche Group**








### Diagnostic platform cobas e 601







# cobas platform >30,000 placements worldwide









## **Roche AD Biomarker Development Program** *Goals*

CSF Abeta42, tTau, and pTau assays (no multiplexing)

- Enable patient selection for treatment with gantenerumab
- Exploring ways to develop stand-alone diagnostic assays





# **General Features** *Abeta42, tTau, pTau assays*

General features	
Assays	Individual Abeta42, tTau, pTau181 (no multiplexing)
Assay format	Sandwich
Sample volume	50 µl per determination
Turn around time	18 min
Degree of automation	fully automated
Platform	cobas e 601
Launchplan	worldwide



#### Thank you for your attention.

Roche Diagnostics Ltd. 6343 Rotkreuz Switzerland

COBAS, COBAS E and LIFE NEEDS ANSWERS are trademarks of Roche

This presentation is our intellectual property. Without our written consent, it shall neither be copied in any manner, nor used for manufacturing, nor communicated to third parties.



